Cervical cancer (CC) ranks fourth among women’s malignancies worldwide and seriously affects women’s health. HSPA5 is a heat shock protein, also known as glucose regulatory protein 78 (GRP78). Upregulation of HSPA5 has been reported to be closely associated with multiple types of tumors. However, the specific role of HSPA5 in cervical cancer has not been discovered. In our study, we explored the prognostic value of HSPA5 in CC. Here, we analyzed the (TCGA) and (UCSC) databases, the analysis of HSPA5 in many tumors types was conducted with the “wilcox. test” method. A False Discovery Rate (FDR) value < 0.05 and Log2 | (fold change, FC) |> 1 were set as the cutoffs. “*”, “**”, and “***” indicate FDR < 0.05, < 0.01, and < 0.001, respectively, and further used human cervical cancer cells for q-PCR and western blotting detection. q-PCR and western blotting results showed that HSPA5 was highly expressed in cervical cancer cells, while it was expressed at low levels in normal cells (P < 0.05).We also analyzed the immunohistochemical data. immunohistochemical analysis results showed that HSPA5 was highly expressed in human cervical cancer, while it was expressed at low levels in normal tissues (P < 0.05). Analysis in TCGA-UCSC showed that the proportion of G3 in the group with high expression of HSPA5 was relatively high (P < 0.05). Enrichment analysis and survival analysis showed that the increased expression of HSPA5 in cervical cancer was related to the survival of CC and was involved in the regulation of biological behavior and molecular signaling pathways of cervical cancer. The correlation analysis of immune checkpoint and immune infiltration showed that HSPA5 was involved in the regulation of immune process of cervical cancer (P < 0.05). Drug sensitivity correlation analysis showed that HSPA5 was a sensitive target for tumor drugs (P < 0.05). In brief, those results suggest that HSPA5 can act as an oncogene of CC development and can serve as an effective predictive biomarker in cervical cancer.

宫颈癌(CC)位居全球女性恶性肿瘤第四位，严重影响女性健康。 HSPA5 是一种热休克蛋白，也称为葡萄糖调节蛋白 78 (GRP78)。据报道，HSPA5 的上调与多种类型的肿瘤密切相关。然而，HSPA5在宫颈癌中的具体作用尚未被发现。在我们的研究中，我们探讨了 HSPA5 在 CC 中的预后价值。在这里，我们分析了（TCGA）和（UCSC）数据库，许多肿瘤类型中的 HSPA5 分析是使用“wilcox.测试方法。错误发现率 (FDR) 值 < 0.05 且 Log2 | （倍数变化，FC）|> 1 被设置为截止值。 “*”、“**”和“***”分别表示FDR < 0.05、< 0.01和< 0.001，并进一步使用人宫颈癌细胞进行q-PCR和western blotting检测。 q-PCR和western blotting结果显示，HSPA5在宫颈癌细胞中高表达，而在正常细胞中低表达（P  < 0.05）。我们还对免疫组化数据进行了分析。免疫组化分析结果显示，HSPA5 在人宫颈癌中高表达，而在正常组织中低表达（P  < 0.05）。 TCGA-UCSC 分析显示，HSPA5 高表达组中 G3 所占比例较高（P  < 0.05）。富集分析和生存分析表明，HSPA5在宫颈癌中的表达增加与CC的生存相关，并参与宫颈癌生物学行为和分子信号通路的调控。免疫检查点与免疫浸润的相关性分析表明，HSPA5参与了宫颈癌免疫过程的调节（P  < 0.05）。药敏相关分析显示HSPA5是肿瘤药物的敏感靶点（P  < 0.05）。简而言之，这些结果表明 HSPA5 可以作为 CC 发展的癌基因，并可以作为宫颈癌的有效预测生物标志物。